{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:24:16Z","timestamp":1790144656780,"version":"4.0.1"},"reference-count":17,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T00:00:00Z","timestamp":1562889600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002997","name":"Dutch Kidney Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0653-6","type":"journal-article","created":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T12:02:51Z","timestamp":1562932971000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8750-5188","authenticated-orcid":false,"given":"Daan P.","family":"Hurkmans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen G. H. P.","family":"Verhoeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kitty","family":"de Leur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjen","family":"Joosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla C.","family":"Baan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H.","family":"von der Th\u00fcsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron H. N.","family":"van Schaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron H. J.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid A. M.","family":"van der Veldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis A.","family":"Hesselink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,7,12]]},"reference":[{"key":"653_CR1","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320\u201330.","journal-title":"N Engl J Med"},{"key":"653_CR2","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.immuni.2016.04.023","volume":"44","author":"MK Callahan","year":"2016","unstructured":"Callahan MK, Postow MA, Wolchok JD. Targeting T cell co-receptors for cancer therapy. Immunity. 2016;44:1069\u201378.","journal-title":"Immunity"},{"issue":"3","key":"653_CR3","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1634\/theoncologist.2018-0195","volume":"24","author":"Luis E. Aguirre","year":"2018","unstructured":"Aguirre LE, Guzman ME, Lopes G, Hurley J. Immune Checkpoint Inhibitors and the Risk of Allograft Rejection: A Comprehensive Analysis on an Emerging Issue. Oncologist. 2019;24:394-401.","journal-title":"The Oncologist"},{"key":"653_CR4","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1046\/j.1365-2133.2002.04976.x","volume":"147","author":"HM Ramsay","year":"2002","unstructured":"Ramsay HM, Fryer AA, Hawley CM, Smith AG, Harden PN. Non-melanoma skin cancer risk in the Queensland renal transplant population. Br J Dermatol. 2002;147:950\u20136.","journal-title":"Br J Dermatol"},{"key":"653_CR5","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1001\/jama.296.23.2823","volume":"296","author":"CM Vajdic","year":"2006","unstructured":"Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, Chapman JR, Webster AC, Kaldor JM, Grulich AE. Cancer incidence before and after kidney transplantation. JAMA. 2006;296:2823\u201331.","journal-title":"JAMA"},{"key":"653_CR6","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1097\/FTD.0000000000000549","volume":"40","author":"J Verhoeven","year":"2018","unstructured":"Verhoeven J, Boer K, Van Schaik RHN, Manintveld OC, Huibers MMH, Baan CC, Hesselink DA. Liquid biopsies to monitor solid organ transplant function: a review of new biomarkers. Ther Drug Monit. 2018;40:515\u201325.","journal-title":"Ther Drug Monit"},{"key":"653_CR7","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1681\/ASN.2016091034","volume":"28","author":"RD Bloom","year":"2017","unstructured":"Bloom RD, Bromberg JS, Poggio ED, Bunnapradist S, Langone AJ, Sood P, Matas AJ, Mehta S, Mannon RB, Sharfuddin A, et al. Cell-free DNA and active rejection in kidney allografts. J Am Soc Nephrol. 2017;28:2221\u201332.","journal-title":"J Am Soc Nephrol"},{"key":"653_CR8","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604\u201312.","journal-title":"Ann Intern Med"},{"key":"653_CR9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.gene.2016.06.033","volume":"590","author":"W Yao","year":"2016","unstructured":"Yao W, Mei C, Nan X, Hui L. Evaluation and comparison of in vitro degradation kinetics of DNA in serum, urine and saliva: a qualitative study. Gene. 2016;590:142\u20138.","journal-title":"Gene"},{"key":"653_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1074-7613(04)00024-X","volume":"20","author":"PT Walsh","year":"2004","unstructured":"Walsh PT, Strom TB, Turka LA. Routes to transplant tolerance versus rejection; the role of cytokines. Immunity. 2004;20:121\u201331.","journal-title":"Immunity"},{"key":"653_CR11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13046-018-0777-4","volume":"37","author":"F Xu","year":"2018","unstructured":"Xu F, Jin T, Zhu Y, Dai C. Immune checkpoint therapy in liver cancer. J Exp Clin Cancer Res. 2018;37:110.","journal-title":"J Exp Clin Cancer Res"},{"key":"653_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1056\/NEJMc1614298","volume":"376","author":"R Barnett","year":"2017","unstructured":"Barnett R, Barta VS, Jhaveri KD. Preserved renal-allograft function and the PD-1 pathway inhibitor nivolumab. N Engl J Med. 2017;376:191\u20132.","journal-title":"N Engl J Med"},{"key":"653_CR13","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/CJI.0000000000000180","volume":"40","author":"AS Kittai","year":"2017","unstructured":"Kittai AS, Oldham H, Cetnar J, Taylor M. Immune checkpoint inhibitors in organ transplant patients. J Immunother. 2017;40:277\u201381.","journal-title":"J Immunother"},{"key":"653_CR14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13256-017-1229-z","volume":"11","author":"V Kwatra","year":"2017","unstructured":"Kwatra V, Karanth NV, Priyadarshana K, Charakidis M. Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report. J Med Case Rep. 2017;11:73.","journal-title":"J Med Case Rep"},{"key":"653_CR15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s40425-016-0171-8","volume":"4","author":"M Ong","year":"2016","unstructured":"Ong M, Ibrahim AM, Bourassa-Blanchette S, Canil C, Fairhead T, Knoll G. Antitumor activity of nivolumab on hemodialysis after renal allograft rejection. J Immunother Cancer. 2016;4:64.","journal-title":"J Immunother Cancer"},{"key":"653_CR16","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1093\/annonc\/mdw130","volume":"27","author":"L Spain","year":"2016","unstructured":"Spain L, Higgins R, Gopalakrishnan K, Turajlic S, Gore M, Larkin J. Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. Ann Oncol. 2016;27:1135\u20137.","journal-title":"Ann Oncol"},{"key":"653_CR17","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.2215\/CJN.01230211","volume":"6","author":"MA Josephson","year":"2011","unstructured":"Josephson MA. Monitoring and managing graft health in the kidney transplant recipient. Clin J Am Soc Nephrol. 2011;6:1774\u201380.","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0653-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0653-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0653-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T20:14:10Z","timestamp":1663964050000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0653-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,12]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["653"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0653-6","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,12]]},"assertion":[{"value":"11 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval of Multomab study (Medical Ethical Board Erasmus MC ref. 16\u2013011), patient signed written informed consent provided before study entry.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Ethics approval of Multomab study (Medical Ethical Board Erasmus MC ref. 16\u2013011), patient signed written informed consent provided before study entry.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AV has an advisory role at BMS. Remaining authors declare no potential conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"182"}}